Alcyone Therapeutics
Biotechnology, 116 John St Ste 300, Lowell, Massachusetts, 01852, United States, 11-50 Employees
Phone Number: 97********
Who is ALCYONE THERAPEUTICS
Alcyone Therapeutics is a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions. The company integrates innovation in neurosc...
Read More
-
Headquarters: 116 John St Ste 300, Lowell, Massachusetts, 01852, United States
-
Date Founded: 2010
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 6282
|
NAICS Code: 54 |
Show More
Does something look wrong? Fix it. | View contact records from ALCYONE THERAPEUTICS
Alcyone Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Alcyone Therapeutics
Answer: Alcyone Therapeutics's headquarters are located at 116 John St Ste 300, Lowell, Massachusetts, 01852, United States
Answer: Alcyone Therapeutics's phone number is 97********
Answer: Alcyone Therapeutics's official website is https://alcyonetx.com
Answer: Alcyone Therapeutics's revenue is $1 Million to $5 Million
Answer: Alcyone Therapeutics's SIC: 6282
Answer: Alcyone Therapeutics's NAICS: 54
Answer: Alcyone Therapeutics has 11-50 employees
Answer: Alcyone Therapeutics is in Biotechnology
Answer: Alcyone Therapeutics contact info: Phone number: 97******** Website: https://alcyonetx.com
Answer: Alcyone Therapeutics is a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions. The company integrates innovation in neuroscience, precision dosing platforms, and manufacturing capabilities to deliver transformative therapies to patients. Alcyone leverages the synergy between FalconTM, the companys proprietary intrathecal precision dosing and biodistribution platform that incorporates deep knowledge of cerebral spinal fluid (CSF) dynamics, computational modeling, and bioengineering, and four novel gene-based therapeutics platforms developed at the Abigail Wexner Research Institute at Nationwide Childrens Hospital (AWRI). This comprehensive approach allows for the optimization of central nervous system (CNS) dosing and delivery to better target the pathophysiology and anatomy specific to various neurological diseases. Alcyones lead programs utilize X chromosome reactivation for X-linked disorders and targets the treatment of Rett syndrome, and gene replacement for the treatment of IGHMBP2-related disorders including spinal muscular atrophy with respiratory distress type 1 (SMARD1) and Charcot Marie Tooth disease type 2S (CMT2S).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month